|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats: What we know so far?显示文摘We read with great interest the article entitled ‘‘Comparative study of the effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats’’ by Ulmer et al. [1]. The aim of this study was to analyse the impact of terlipressin versus splenectomy on postoperative liver function and liver regeneration in rats undergoing 70% partial hepatectomy. Ulmer and his colleagues concluded that neither the administration of terlipressin nor splenectomy improved liver regeneration after 70% partial hepatectomy in rats. This is a very interesting research in our understanding regarding the study of postoperative liver failure and liver regeneration after modulation of portal vein pressure. However, there are some questions which demand further consideration. | antonios athanasiou eleftherios spartalis mairead hennessy michael spartalis demetrios moris christos damaskos emmanouil pikoulis | 2018 | Hepatobiliary & Pancreatic Diseases International2018，17，1： | 5 |
| 2 | Cytokines as biomarkers of inflammatory response after open versus endovascular repair of abdominal aortic aneurysms: a systematic review显示文摘一个腹的大动脉的动脉瘤(AAA ) 的修理是与有煽动性的串联的随后的激活的神经质、新陈代谢的压力相关的反应有关的一个高风险的外科的过程。与开的修理相对照(或) , endovascular 大动脉的动脉瘤修理(EVAR ) 由为更少提供广泛的切口,解剖,和织物操作似乎是手术后的压力到减少。然而,这些有益的效果可以是由代谢物在用在 endovascular 的导管的血栓的 intra 钠操作期间修理的 cytokines 和 arachidonic 酸的版本的偏移量,导致全身的煽动性的反应(先生) ,它是临床上叫的培植以后的症候群。在我们比较了的这系统的评论或与 EVAR,以 post-interventional,从改变导致传播 cytokine 的煽动性的反应铺平。我们寻求了在 EVAR 以后关于培植以后的症候群总结所有最近的证据。我们寻找了为临床的研究作为煽动性的反应的部分在 cytokines 的版本上报导在以后的 Medline (PubMed ) , ClinicalTrials.gov 和 Cochrane 图书馆开 / 常规并且 AAA 的 endovascular 修理。我们鉴别 17 学习检验 cytokine 层次在以后或对 EVAR。或似乎特别地比 EVAR 与一位更大的先生被联系,由增加的 cytokine 层次证实了 IL-6 和 IL-8 而 IL-1, IL-10 和 TNF- 出现了,冲突在二之间的结果或没有差别组织。聚酯 endografts 看起来断然在 EVAR 以后与培植以后的症候群的发生被相关。未来大未来的研究被保证位于在 surgical 以后的 cytokine 相互作用下面描出的机制煽动性的反应背景。 | Diamantis I TSILIMIGRAS Fragiska SIGALA Georgios KARAOLANIS Ioannis NTANASIS-STATHOPOULOS Eleftherios SPARTALIS Michael SPARTALIS Nikolaos PATELIS Alexandros PAPALAMPROS Chandler LONG Demetrios MORIS | 2018 | Acta Pharmacologica Sinica2018，39，7： | 5 |
| 3 | Novel approaches for the treatment of ventricular tachycardia显示文摘Ventricular tachycardia(VT) is a crucial cause of sudden cardiac death(SCD) and a primary cause of mortality and morbidity in patients with structural cardiac disease. VT includes clinical disorders varying from benign to lifethreatening. Most life-threatening episodes are correlated with coronary artery disease, but the risk of SCD varies in certain populations, with various underlying heart conditions, specific family history, and genetic variants. The targets of VT management are symptom alleviation, improved quality of life, reduced implantable cardioverter defibrillator shocks, prevention of reduction of left ventricular function, reduced risk of SCD, and improved overall survival. Antiarrhythmic drug therapy and endocardial catheter ablation remains the cornerstone of guideline-endorsed VT treatment strategies in patients with structural cardiac abnormalities. Novel strategies such as epicardial ablation, surgical cryoablation, transcoronary alcohol ablation, pre-procedural imaging, and stereotactic ablative radiotherapy are an appealing area of res-earch. In this review, we gathered all recent advances in innovative therapies as well as experimental evidence focusing on different aspects of VT treatment that could be significant for future favorable clinical applications. | Michael Spartalis Eleftherios Spartalis Eleni Tzatzaki Diamantis I Tsilimigras Demetrios Moris Christos Kontogiannis Efthimios Livanis Dimitrios C Iliopoulos Vassilis Voudris George N Theodorakis | 2018 | World Journal of Cardiology2018，10，7： | 2 |
| 4 | Inherited arrhythmias and gene therapy: Are there any ethical considerations to take into account?显示文摘Interventional electrophysiology represents a relatively recent subspecialty within the field of cardiology.In the past half-century,there has been significant advan-cement in the development and implementation of innovative ablation treatments and approaches.However,the treatment of arrhythmias continues to be inade-quate.Several arrhythmias,such as ventricular tachycardia and atrial fibrillation,pose significant challenges in terms of therapeutic efficacy,whether through interventional procedures or the administration of antiarrhythmic drugs.Cardio-logists are engaged in ongoing research to explore innovative methodologies,such as genome editing,with the purpose of effectively managing arrhythmias and meeting the growing needs of patients afflicted with rhythm disturbances.The field of genome editing has significant promise and has the potential to serve as a highly effective personalized therapy for rhythm disorders in patients.However,several ethical issues must be considered. | Michael Spartalis Eleftherios Spartalis Gerasimos Siasos | 2023 | World Journal of Cardiology2023，15，12： | 1 |
| 5 | Role of platelet-rich plasma in ischemic heart disease: An update on the latest evidence显示文摘Myocardial infarction is the most common cause of congestive heart failure. Novel strategies such as directly reprogramming cardiac fibroblasts into cardiomyocytes are an exciting area of investigation for repair of injured myocardial tissue. The ultimate goal is to rebuild functional myocardium by transplanting exogenous stem cells or by activating native stem cells to induce endogenous repair. Cell-based myocardial restoration, however, has not penetrated broad clinical practice yet. Plateletrich plasma, an autologous fractionation of whole blood containing high concentrations of growth factors, has been shown to safely and effectively enhance healing and angiogenesis primarily by reparative cell signaling. In this review, we collected all recent advances in novel therapies as well as experimental evidence demonstrating the role of platelet-rich plasma in ischemic heart disease, focusing on aspects that might be important for future successful clinical application. | Eleftherios Spartalis Periklis Tomos Demetrios Moris Antonios Athanasiou Charalampos Markakis Michael D Spartalis Theodore Troupis Dimitrios Dimitroulis Despina Perrea | 2015 | World Journal of Cardiology2015，7，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员